drugset
drugset / Trial / NCT07067346

Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma

NCT07067346 ↗

Phase 0 Recruiting 10 enrolled Sichuan University
NaSequentialOpen-labelTreatment

Summary

Radiopharmaceutical in Relapsed/Refractory Neuroblastoma

Timeline

Start
2025-07-18
Primary completion
2026-06-30
Completion
2026-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject IR-101 Other / unclassified — —

Indications

neuroblastoma